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Iron deficiency is the most common nutritional disorder worldwide with substantial impact on health and economy. Current treatments
predominantly rely on soluble ironwhich adversely affects the gastrointestinal tract.We have developed organic acid-modified Fe(III) oxo-hydroxide
nanomaterials, here termed nano Fe(III), as alternative safe iron delivery agents. Nano Fe(III) absorption in humans correlated with serum iron
increase (P b 0.0001) and direct in vitro cellular uptake (P = 0.001), but not with gastric solubility. The most promising preparation (iron hydroxide
adipate tartrate: IHAT) showed ~80% relative bioavailability to Fe(II) sulfate in humans and, in a rodentmodel, IHATwas equivalent to Fe(II) sulfate
at repleting haemoglobin. Furthermore, IHAT did not accumulate in the intestinal mucosa and, unlike Fe(II) sulfate, promoted a beneficial
microbiota. In cellular models, IHAT was 14-fold less toxic than Fe(II) sulfate/ascorbate. Nano Fe(III) manifests minimal acute intestinal toxicity in
cellular and murine models and shows efficacy at treating iron deficiency anaemia.
From the Clinical Editor: This paper reports the development of novel nano-Fe(III) formulations, with the goal of achieving a magnitude
less intestinal toxicity and excellent bioavailability in the treatment of iron deficiency anemia. Out of the tested preparations, iron hydroxide
adipate tartrate met the above criteria, and may become an important tool in addressing this common condition.
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target diseases for cure and prevention.1 However, despite
considerable global efforts with oral iron supplementation and
fortification, iron deficiency remains the most common and
widespread nutritional disorder in the world, affecting 4 billion
people.2-6 Achieving practicable strategies for iron fortification,
ensuring the bioavailability of the iron used and obviating the
side effects of oral iron supplements, are some of the well-known
challenges for fortification/supplementation programs. However,
in recent years, more significant questions are being posed by
safety data outcomes from oral iron studies. A negative impact
on the commensal flora, especially suppression of Lactobacillus,7
and an enhancement of systemic infection for at-risk populations8,9
have been convincingly demonstrated in oral iron supplementation/
fortification studies in humans. Most recently, a marked
enhancement of colonic carcinogenesis by soluble luminal
(chelated) iron has been demonstrated in mice,10 including thosedroxide delivers safe iron that is well absorbed and utilised in humans.
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Table 1
Characteristics of the Fe(III) oxo-hydroxide materials investigated.
Test compound Ligands Molar ratio
of ligands: Fe
Physical form Hydrodynamic diameter in H2O
i (nm)
Mean D(v)0.1 D(v)0.9
Nano Fe(III) (a) Tartaric acid (T)
Adipic acid (A)
1:1:2 (T:A:Fe) Dry powder 5.0 (0.4) 3.0 (0.7)
7.70 (0.08)
Nano Fe(III) (b) Tartaric acid (T)
Succinic acid (S)
1:1:2 (T:S:Fe) Dry powder 4.9 (0.2) 2.9 (0.2)
7.6 (0.2)
Nano Fe(III) (c) Tartaric acid (T)
Succinic acid (S)
1:6:2 (T:S:Fe) Dry powder 7.3 (0.5) 3.7 (1.2)
11.6 (0.5)
Nano Fe(III) (d) Gluconic acid (G)
Adipic acid (A)
1:1:2 (G:A:Fe) Dry powder 2.88 (0.09) 1.76 (0.09)
4.4 (0.1)
Nano Fe(III) (e)ii Tartaric acid (T)
Adipic acid (A)
1:1:2 (T:A:Fe) Aqueous suspension 4.80 (0.09) 2.8 (0.2)
7.39 (0.07)
Fe(III) (OH)3
iii N/A N/A Dry powder N1000 (agglomerated)
N/A—not applicable.
i Nano Fe(III) (a)–(d) and Fe(III) (OH)3 dried materials were resuspended in H2OUHP at [Fe] = 8 mM and nano Fe(III) (e) was diluted in H2OUHP to
[Fe] = 8 mM. All nano Fe(III) materials were sonicated for 5 minutes and then centrifuged at 4000 ×g for 5 minutes and filter-sterilized through 0.2 μm filters
prior to nanosizing. Micron-sized Fe(III)(OH)3 was sonicated and centrifuged under the same conditions but was not filtered prior to nanosizing. Data are
presented as mean (SD) hydrodynamic diameter of 3 measurements, with the lower 10% [d(v)0.1 (SD)] and upper 90% [d(v)0.9 (SD)] percentile values.
ii Nano Fe(III) (e) is the same formulation as nano Fe(III) (a), but was used in the human study in a colloidal suspension (i.e. as synthesised) without drying.
iii Refers to standard unmodified synthetic Fe(III) oxo-hydroxide (i.e. synthetic 2-line ferrihydrite).
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colon cancer in humans.11
The physicochemical forms of iron that are commonly used
for supplementation and/or fortification may contribute to
significant undesirable effects. Iron that remains soluble in the
intestinal lumen is likely to be bioavailable but, equally, may be
available for other processes including uptake by commensal
flora and colonic epithelial cells, and facile redox-cycling in the
gut lumen. Indeed, the generation of harmful free-radicals
through Fenton chemistry which can cause inflammation and
oxidative stress in the intestinal mucosa has been linked to
available luminal iron in several studies. Carrier et al have shown
that in rats with DSS-induced colitis, ferrous sulfate supplemen-
tation increased colonic and plasma lipid peroxides and overall
disease activity.12 Increased oxidative stress following oral iron
therapy has been supported in clinical studies in inflammatory
bowel disease13 and in healthy subjects.14,15 Fe(II) sulfate was
also shown to be involved in the onset of chronic disease in a
murine ileitis model.16 In the DSS-induced colitis mouse model,
Seril and colleagues found a remarkable increase in tumour
incidence (from 19 to 88%) by doubling the amount of iron
in the diet using sodium Fe(III) EDTA.10 Furthermore,
recent reports of a transient increase in undesirable non-
transferrin bound iron (NTBI)12,14-18 in the systemic
circulation after oral supplementation with soluble iron
may be a consequence of iron entering the circulation at a
rate that exceeds the rate of transferrin binding. NTBI has
been associated with an increased risk of infection and
coronary heart disease.19-22
Recently, we have developed 5-10 nm hydro-disperse
particles of iron oxo-hydroxide that are modified synthetically
with the addition of tartaric and adipic acids, and mimic23-25 the
well-absorbed ferritin core.26-31 These same ligand-modified
nano iron oxo-hydroxide particles [i.e. with tartaric (T) andadipic (A) acids used as ligands at a ratio 1:1:2 (T:A:Fe)]
have been shown in cellular and animal models to be taken
up by intestinal epithelial cells via a mechanism independent
of luminal redox activity and, therefore, independent of
apical DMT1.23,25 Uptake, probably, is by endocytosis
followed by lysosomal dissolution to release bioavailable
iron,25 although the precise pathway is incompletely
elucidated. Importantly, we have shown in murine models that
absorption of iron from these modified nano iron oxo-hydroxide
particles is regulated by normal iron homeostasis mechanisms:
i.e. through the action of hepcidin on the iron exporter
ferroportin.24 Data in humans, however, are lacking. Hence,
in this work, we have engineered five different structures with
near identical physical properties (size) but divergent
chemical properties (acid solubility) to determine (a) the
bioavailability of these synthetic Fe(III) nanomaterials in
volunteers, (b) the role of gastric acid dissolution versus
direct cellular uptake of the nanoparticles in determining
bioavailability and (c) the rates of absorption versus Fe(II) sulfate.
Finally, we have made some initial safety measurements of the
most bioavailable nano Fe(III) material and we conclude that this
‘ferritin core mimetic’ may provide a solution for safe and
efficacious oral iron supplementation.Methods
Iron materials
Non enteric-coated Fe(II) sulfate tablets (Actavis, Barnstaple,
UK), equivalent to 60 mg Fe/tablet, were purchased from a
local pharmacy. The nanoparticulate ligand-modified Fe(III)
poly oxo-hydroxides, here referred to as nano Fe(III), were
produced using food grade reagents following the protocol
Figure 1. Solubility and cellular uptake of nano Fe(III). (A)Acid dissolution at pH 3.0 in 9 g/L NaCl. Data are for different formulations of ligand-modified Fe
(III) oxo-hydroxides: nano Fe(III) (a)- ligands are tartaric (T) and adipic (A) acids at a ratio 1:1:2 (T:A:Fe) and the material was dried prior to re-suspension; nano Fe
(III) (b)—ligands are tartaric (T) and succinic (S) acids at a ratio 1:1:2 (T:S:Fe) and the material was dried prior to re-suspension; nano Fe(III) (c)- ligands are tartaric
(T) and succinic (S) acids at a ratio 1:6:2 (T:S:Fe) and thematerial was dried prior to re-suspension; nano Fe(III) (d)- ligands are gluconic (G) and adipic (A) acids at a
ratio 1:1:2 (G:A:Fe) and the material was dried prior to re-suspension; nano Fe(III) (e)- ligands are tartaric (T) and adipic (A) acids at a ratio 1:1:2 (T:A:Fe) and the
material was used as a colloidal suspension (i.e. as synthesised) without drying (more details in Table 1). Negative and positive controls are, respectively, unmodified
Fe(III) oxo-hydroxide (Fe(III)(OH)3) and Fe(III) maltolate (Fe(III) maltol). Data are shown for the two independent replicates. Dotted black lines show 0 and 100%
solubility. All data were obtained bymeasuring the iron concentration in the supernatant following ultrafiltration (Mr 3000 cut-off). (B)Dispersion of the different iron
materials in the BSS uptake medium, used for the Caco-2 cell experiments, as assessed by the fractional percentage of microparticulate (black), nanoparticulate (red)
and soluble (white) Fe for each Fe material. Values are mean ± SD of three independent replicates. (C) Cellular iron (open bars) and ferritin (closed bars) levels in
Caco-2 cells 23 hours following a one hour exposure to 0.5 mM Fe as unmodified Fe(III) oxo-hydroxide (Fe(III)(OH)3), ligand-modified Fe(III) oxo-hydroxides
(nano Fe(III) (a-e)), or soluble Fe(III) maltolate (Fe(III)maltol). Results are mean ± SD of three independent experiments (each condition tested in triplicate
wells within each experiment). Statistical comparisons in relation to the soluble control, Fe(III) maltol: ***, P = 0.0008; ****, P b 0.0001 for cellular iron;
##, P = 0.003; ###, P = 0.0002 and ####, P b 0.0001 for ferritin. (D) Pearson's correlation between the solubility of nano Fe(III) at pH3.0 after 15 minutes and
cellular iron levels of Caco-2 cells following exposure to nano Fe(III). (E) Pearson's correlation between cellular ferritin levels and cellular iron levels in Caco-2 cell
monolayers following exposure to nano Fe(III). For panels (D) and (E), values are mean ± SD, in both the X and Y directions. Where not apparent, the error bars are
smaller than the symbol size. Data points are labelled with the nano Fe(III) preparation codes (a–e).
1879D.I.A. Pereira et al / Nanomedicine: Nanotechnology, Biology, and Medicine 10 (2014) 1877–1886described by Powell et al23 Further synthetic and analytical
details are supplied in the Supplementary Materials. The
ligand composition and particle size of each of the five
different nano Fe(III) materials investigated as well as
unmodified iron oxo-hydroxide (synthetic ferrihydrite) are
presented in Table 1.Acid lability
The solubility of the iron materials was determined at pH 3.0
(lower end of the pH range of the postprandial gastric
environment32) using an autotitrator. Further details are provided
in the Supplementary Materials.
Figure 2. Absorption of iron from nano Fe(III) in iron-deficient women.
(A) Relative bioavailability values (RBV) in relation to Fe(II) sulfate
(100%). Percentage RBV for the nano Fe(III) preparations was calculated
from the incorporation of labelled 58Fe into red blood cells, as measured by
ICP-MS 14 days after ingestion of a single-dose of labelled compound
(60 mg elemental Fe). Absorption from Fe(II) sulfate was estimated from the
serum Fe curve with validated algorithms.39,66 Nano Fe(III) (a)—ligands are
tartaric (T) and adipic (A) acids at a ratio 1:1:2 (T:A:Fe) and the material was
dried prior to re-suspension; nano Fe(III) (b)—ligands are tartaric (T) and
succinic (S) acids at a ratio 1:1:2 (T:S:Fe) and the material was dried prior to
re-suspension; nano Fe(III) (c)—ligands are tartaric (T) and succinic (S) acids
at a ratio 1:6:2 (T:S:Fe) and the material was dried prior to re-suspension;
nano Fe(III) (d)— ligands are gluconic (G) and adipic (A) acids at a ratio
1:1:2 (G:A:Fe) and the material was dried prior to re-suspension; nano Fe(III)
(e)—ligands are tartaric (T) and adipic (A) acids at a ratio 1:1:2 (T:A:Fe) and
the material was used as a colloidal suspension (i.e. as synthesised) without
drying (more details in Table 1). Controls are unmodified Fe(III) oxo-
hydroxide (Fe(III)(OH)3) and an ‘unformulated’ mixture of Fe(III) chloride,
tartaric acid and adipic acid in the same ratios as those used in nano Fe(III)
(a). Box and whisker plots show median, minimum and maximum for n = 2
(Fe(III) (OH)3) or n = 4 (all other iron materials). **, P = 0.004.
(B) Pearson's correlation between cellular iron levels in Caco-2 cells
exposed to nano Fe(III) (preparations a-e) and relative bioavailability values
(%RBV) of the same materials, as shown in Figures 1, C and 2, A. Nano Fe
(III) (c) (shown in red triangle) was excluded from the correlation parameters
presented in the panel (see Results and Discussion). Values are shown as
mean ± SD in both the X and Y directions. Data points are labelled with the
nano Fe(III) preparation codes (a-e).
Figure 3. Serum iron absorption following ingestion of a single-dose of
the different Fe materials in iron-deficient women. Serum iron increase
(A) and transferrin saturation increase (B) following a single dose of nano Fe
(III) preparation (a) (closed circles) and Fe(II) sulfate (open triangles). Values
are shown as mean and error bars represent SEM (n = 4). Transferrin
saturation was defined as serum iron divided by total iron binding capacity
and expressed as a percentage. (C-D) Pearson's correlation between
percentage of iron absorption (calculated from the red cell incorporation of
58Fe) and maximum serum Fe increase (C) or rate of serum iron increase
(D) for the five nano Fe(III) materials. Data points correspond to each
individual study participant and are colour coded to reflect the different nano
Fe(III) preparations: closed diamonds, nano Fe(III) (a); open triangles, nano
Fe(III) (b); open circles, nano Fe(III) (c); closed triangles, nano Fe(III)
(d); closed circles, nano Fe(III) (e). Nano Fe(III) (a)—ligands are tartaric
(T) and adipic (A) acids at a ratio 1:1:2 (T:A:Fe) and thematerial was dried prior
to re-suspension; nano Fe(III) (b)—ligands are tartaric (T) and succinic (S) acids
at a ratio 1:1:2 (T:S:Fe) and the material was dried prior to re-suspension; nano
Fe(III) (c)—ligands are tartaric (T) and succinic (S) acids at a ratio 1:6:2 (T:S:
Fe) and the material was dried prior to re-suspension; nano Fe(III) (d)—ligands
are gluconic (G) and adipic (A) acids at a ratio 1:1:2 (G:A:Fe) and the material
was dried prior to re-suspension; nano Fe(III) (e)— ligands are tartaric (T) and
adipic (A) acids at a ratio 1:1:2 (T:A:Fe) and thematerial was used as a colloidal
suspension (i.e. as synthesised) without drying (more details in Table 1).
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Cellular uptake studies were carried out in Caco-2 cells as
described previously,25 and specific full details are in the
Supplementary Materials. Values for uptake are reported as total
cellular Fe content, and include not only Fe that is internalised by
the cell but also Fe that remains associated with the cell
membrane after washing. All data were normalised to total cell
protein content and corrected for control levels (i.e. levels in cells
incubated with BSS not supplemented with iron). The soluble
iron material used as a control in the cellular assays was Fe(III)
Figure 4. Effects of nano Fe(III) on cell viability and the intestinal microbiome of rats. (A) Viability of Caco-2 (red lines) and HT-29 (bold blue lines) cells
exposed to increasing concentrations of Fe as nano Fe(III) (a) (ligands are tartaric (T) and adipic (A) acids at a ratio 1:1:2 (T:A:Fe) and the material was dried
prior to re-suspension) for 24 (solid line) or 48 (dashed line) hours. Fe(II)-ascorbate (molar ratio 1:10) data in Caco-2 cells are shown in black. Results shown are
mean ± SD of three independent experiments (each condition tested in triplicate wells per experiment). **, P b 0.01; ***, P b 0.001; ****, P b 0.0001 in
relation to control cells incubated in the absence of the iron materials (100% viability). (B)Haemoglobin levels of anaemic Sprague–Dawley male rats following
14 days dietary supplementation with nano Fe(III) (a) or Fe(II) sulfate (FeSO4). Data are shown for each animal at baseline (d0) and after 14 days (d14) iron
supplementation. Data for the reference iron-replete group (i.e. rats fed the standard iron-sufficient diet throughout) are also shown. *, P = 0.04; **, P = 0.01
corresponding to the paired t test between day 0 and day 14 for FeSO4 and nano Fe(III) (a), respectively. (C) Characterisation of the faecal microbiota at the
genus level of rats receiving either Fe(II) sulfate or nano Fe(III) (a) at baseline (d0) and after 14 days supplementation (d14). Proportions (mean ± SEM) of the
three predominant genera Lactobacillus (D), Bacteroides (E) and Escherichia (F)) are shown at baseline and at day 14. *, P = 0.03. The differences between
Fe(II) sulfate and nano Fe(III) (a) did not reach significance for Lactobacillus (P = 0.1) or Bacteroides (P = 0.2). (G) Paraffin-embedded sections of the small
intestine of animals supplemented with (i) nano Fe(III) (a) or (ii) Fe(II) sulfate without detectable iron staining (Perls' Prussian Blue). Scale bar represents
100 μm.
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control cells not exposed to iron were between 2 and 10 ng/mg
cell protein in line with values previously reported for non-
iron supplemented Caco-2 cells.33,34 Cellular iron levels
in these same control cells were negligible (i.e. below the ICP-
OES detection limit of 0.05 μM once digested and diluted
for analysis—i.e. below 1.25 μM or 1 pmol/μg cell protein
in undiluted cell lysate). The background iron content of BSS
not supplemented with iron was 0.0010 ± 0.0009 mM and
this was negligible in relation to the iron content added to the
media (i.e. 0.5 mM).Cell viability assay
Cell viability was assessed in Caco-2 and HT-29 cells using a
tetrazolium-based colorimetric assay as detailed in the Supple-
mentary Materials. A mixture of Fe(II) sulfate and ascorbate
(molar ratio 1:10) was used as a positive control in Caco-2 cells.
Animal study
This study was carried out in strict accordance with the
Australian Code of Practice for the Care and Use of Animals
for Scientific Purposes. Every effort was made to minimise
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Berghofer Medical Research Institute Animal Ethics Committee.
Twenty one day old male Sprague–Dawley rats (n = 6) were
housed individually and fed ad libitum an iron deficient diet
(iron content 3 to 5 mg/kg wet weight)35 for 6 weeks prior to the
start of the study (see Supplementary Table S1 for the diet
composition). Following the iron depletion period, the
animals were administered ad libitum one of the two test
diets (n = 3 per group) for 14 days. The test diets were
equivalent to the Fe deficient diet,35 but were supplemented
with either 20 mg Fe/kg diet as Fe(II) sulfate or 20 mg Fe/kg diet as
nano Fe(III). Three additional rats were fed an Fe-sufficient
diet (Fe content: 50 mg Fe/kg diet as Fe(III) citrate35)
ad libitum throughout the whole study and were used for
comparison in the histological assessment. Further details are in
the Supplementary Materials.
Faecal microbiota analysis
The composition of the faecal microbiota was determined using
454-pyrosequencing as described in Supplementary Materials.Human study
Design and subjects
Bioavailability of the different nano Fe materials was
determined in a single-dose iron absorption study in mild-
moderately iron deficient, pre-menopausal female subjects (18–
45 years). The study was approved by the U.K. National
Research Ethics Service (06/Q0102/47) and carries Clinical-
Trials.gov registration number, NCT01991600. Written individ-
ual informed consent was obtained prior to enrolment in the
study. The demographic and anthropometric characteristics of
study participants are presented in the Supplementary Table S2.
Eligible participants were invited to two study visits (day 1 and
day 14). The participants ingested, on day 1 of the study, one of
the test nano iron formulations (58 ± 7 mg elemental iron
equivalent), and 14 days later, one Fe(II) sulphate tablet (60 mg
elemental iron equivalent), which is still the gold standard of oral
iron therapy. Five ligand-modified Fe(III) oxo-hydroxide
materials [nano Fe(III) (a-e)] (n = 4 per group) were tested
alongside unmodified Fe(III) oxo-hydroxide [Fe(III)(OH)3]
(n = 2) and a control mixture containing Fe(III) chloride, tartaric
and adipic acids (n = 4) in the same quantities as those used for
nano Fe(III) (a). Twenty six women completed the study. Details
of the eligibility criteria, blood analysis and study visit protocols
are provided in Supplementary Materials. Absorption of the nano
Fe(III) materials was determined by erythrocyte incorporation
of 58Fe36 as described in Supplementary Materials. Relative
bioavailability values (RBV) for nano Fe(III) were determined
by standard methodology, namely dividing iron absorption from
nano Fe(III) by iron absorption from ferrous sulfate for each
study subject. RBV are expressed in percentage.Results
Five different nano Fe(III) oxo-hydroxide materials
were investigated as potential iron supplements: to achievethis, the native oxo-hydroxide structure of these materials
(i.e. synthetic ferrihydrite) was modified by the purposeful
incorporation of small organic ligands (see Table 1 as detailed in
Methods). All materials were fine nanoparticulate structures
in aqueous suspension, with mean hydrodynamic diameters
b10 nm, and thus they were too small to allow particle charge
(i.e. zeta potential) measurements.Solubility at low pH
It is commonly considered that an effective iron supplement
must be soluble under the conditions found in the gastrointestinal
tract and, typically, this is achieved in the stomach. Using a low
pH to simulate gastric dissolution, the differing nano Fe(III)
materials showed ~3-fold variation in absolute solubility at
90 minutes. Initial dissolution was always very rapid (within the
minimum of 5 minutes required to set up the assay) and was then
very slow or plateaued across the remaining 90 minutes
(Figure 1, A). Acid solubility of the positive control material
[soluble Fe(III) maltolate] and the negative control [unmodified
Fe(III) oxo-hydroxide] (i.e. synthetic ferrihydrite) were, as
expected, 100% and minimally soluble respectively (Figure 1, A).Cellular uptake andutilisation and relationship to acid solubility
All nano Fe(III) materials were N95% dispersed when added
to the cell culture medium (Figure 1, B). As expected, Fe(III)
maltolate was almost fully soluble and the unmodified Fe(III)
oxo-hydroxide was insoluble (Figure 1, B). Surprisingly, acid
solubility (Figure 1, A) of the nano Fe(III) materials correlated
inversely with their uptake by Caco-2 cells (Figure 1, C and D;
r = −0.91, P = 0.03). However, cellular utilisation (i.e. ferritin
formation by the cells) correlated very closely with iron uptake
by Caco-2 cells (Figure 1, E; r = 0.978, P = 0.004).Oral bioavailability of the nano Fe (III) supplements in
humans and relationship to in vitro characteristics
Using the gold standard measurement of isotopic incorpora-
tion into haemoglobin we confirmed that, as previously reported
in human and rodent feeding studies,23,37,38 Fe(III) oxo-hydroxide
that had not been ligand-modified (i.e. unmodified synthetic
ferrihydrite) was poorly absorbed/utilised in iron deficient subjects
[P b 0.0001 versus Fe(II) sulfate]. Its bioavailability was 5-fold
lower than the average of the ligand-modified nano Fe(III)
materials (Figure 2, A).
The utilisation of iron following oral dosing of the nano Fe(III)
materials in iron deficient subjects (Figure 2, A) followed the
predicted utilisation from cellular experiments, with the exception
of preparation (c) (Figure 2,B; r = 0.999,P = 0.001). Preparations
(a) and (c) appeared identical in terms of acid dissolution, cellular
uptake and cellular ferritin formation in vitro (Figure 1), but iron
from preparation (a) was absorbed in vivo at ~80% the efficiency
of Fe(II) sulfate while, for preparation (c) the efficiency was
only ~15% (Figure 2, A). Gastric acid solubility appeared
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materials (r = −0.90) albeit not quite significant (P = 0.1).
Of the 5 different nano Fe(III) materials, preparation (a) was
best absorbed/utilised in vivo (Figure 2, A). However, when
similar doses of Fe(III) chloride plus tartaric and adipic acids were
dosed together in vivo, at the same ratios used in the synthesis of
preparation (a), they yielded only about one third of the iron
absorption [P = 0.004 versus preparation (a)] (Figure 2, A).
Ferrous sulfate was not labelled so formal comparisons
between this and the nano Fe(III) preparations, in terms of rate of
Fe absorption versus absolute Fe absorption, were not possible.
However, in all cases, the orally dosed nano Fe(III) materials
raised serum iron levels and transferrin saturation slowly and less
effectively (at 4 hours) than the same dose of iron from Fe(II)
sulfate [e.g. Figure 3, A and B for nano Fe(III)]. Nonetheless, as
stated above, whether these were disproportionally low when
considering the absolute absorption compared to the same
measures for ferrous sulfate could not be addressed. Indeed,
absolute absorption of all nano Fe(III) materials (determined
from the 58Fe red-cell incorporation) correlated with maximum
serum iron increase (Figure 3, C; r = 0.926, P b 0.0001) and
the rate of serum iron increase (Figure 3, D; r = 0.805,
P b 0.0001), although variation for some of the nano iron
formulations [for example nano iron (a)] was high. As such, the
linear association between absolute absorption and percentage of
recovery, as defined by Conway et al,39 is 2.2 ± 0.1 x %
recovery at maximum serum Fe (r = 0.908, P b 0.0001) for
nano Fe(III) whereas the published data for ferrous sulfate
suggest a markedly higher slope for the same relationship
(namely 8.8 ± 0.9, r = 0.78, P b 0.0001).39In vitro and in vivo toxicity assessment
Since preparation nano Fe(III) (a), namely iron hydroxide
adipate tartrate or IHAT, appeared most promising for translation
to clinical/nutritional practice, we next considered the effects of
this preparation in vitro on cell viability and in vivo on colonic
bacterial diversity.
At therapeutically useful levels, nano Fe(III) (a) was not
cytotoxic to either Caco-2 or HT-29 cells based on cell viability
assays (Figure 4, A). Loss of viability was observed only for
[Fe] ≥ 4 mM, which is much higher than the anticipated iron
concentrations in the small intestine following supplementation
(ca. 0.2 mM) assuming therapeutic doses of 60 mg iron up to
three times a day.40 In contrast, Fe(II) sulfate:ascorbate (molar
ratio 1:10) was found to reduce Caco-2 cell viability at Fe
concentrations ≥0.5 mM (Figure 4, A).
To further investigate the effects of nano Fe(III) on the
intestinal mucosa and faecal microbiota, we carried out a pilot
study in rats. For 14 days following a 6 week iron depletion
period, rats were fed either preparation nano Fe(III) (a) or Fe(II)
sulfate. The preparations provided equal repletion in haemoglobin
(Figure 4, B) and, during this period, food intake and changes in
body weight were consistent with those of a non-iron deficient
reference group (Supplementary Table S3).
We also compared the faecal microbiota profile of
rats supplemented with preparation nano Fe(III) (a) to thosegiven Fe(II) sulfate by pyrosequencing of the gene encoding 16S
RNA. We obtained an average of 5144 sequences per animal
after quality control. There were no statistically significant
differences in total bacterial diversity, as assessed by Shannon's
diversity and evenness indices, or in the number of total
operational taxonomic units (OTUs) between the two treatment
groups (Supplementary Table S4). However, the nano Fe(III)
supplemented group showed an apparent increase in the
proportion of Lactobacillus spp. and a decrease in Bacteroides
spp. in relation to the animals supplemented with Fe(II) sulfate
(Figure 4, C, D, and E). There was a high prevalence of the
genus Escherichia in the iron deficient animals (day 0) and this
appeared to decrease following iron supplementation with nano
Fe(III) (a) and to some extent also with Fe(II) sulfate (Figure 4,
F). Finally, similar to rats fed a control diet, there was no
detectable iron deposition in the mucosa of the small intestine of
nano Fe(III)-fed rats (Figure 4, G; online Supplement Figure 1).Discussion
Fe(III) nanoparticles deserve careful attention as potential
therapeutic agents for three reasons. First, iron oxo-hydroxides
represent one of the luminally-formed digestion products of
dietary non-haem iron.25,41 Secondly, dietary ferritin is a
commonly ingested Fe(III) nanoparticle of protein-encapsulated
ferrihydrite31,42 and its potential role in biofortification, such as
through the Global HarvestPlus initiative,43-46 has gained much
attention. Thirdly, nano Fe(III)-based supplements/fortificants could
provide bioavailable iron and our preliminary data suggest that
gastrointestinal and systemic adverse-effects may be minimised.
By doping the synthetic Fe(III) poly oxo-hydroxide structure
with low molecular weight dietary ligands, we have been able to
achieve a small series (a–e) of fine nanodisperse Fe(III)
structures (b10 nm diameter when aquated) with markedly
differing in vitro solubility. These nanodisperse Fe(III) structures
are composed of synthetic 2-line ferrihydrite primary particles
modified and destabilised by the introduction of the organic
acids, as extensively characterised elsewhere.23 Destabilisation
of ferrihydrite primary particles in this fashion resembles that
reported for the iron oxo-hydroxide core in ferritin.31,47
Acid solubility of iron compounds has been consistently
reported to be a good proxy for cellular iron uptake and in vivo
bioabailability.48-54 However, for the five nano Fe(III) materials
presented herein, acid solubility was inversely associated to their
in vitro cellular uptake (Figure 1, D), which correlated with
bioavailability in humans (Figure 2, B). To be able to draw this
conclusion, it was necessary to investigate cellular uptake/
utilisation of non-agglomerated and non-solubilised whole
nanoparticles (i.e. assuming that they ‘survive’ gastric digestion).
Hence we have used a Caco-2 cell assay optimised for our work
with nano iron25 rather than themore sophisticatedmodel developed
by Glahn and colleagues, for example, for iron materials where
solubilisation in the stomach dictates absorption.55
Moreover, for four of the five materials, bioavailability was
clearly positively associated with cellular uptake, suggesting that
direct cellular uptake/adhesion, rather than gastric dissolution,
were drivers of bioavailability. Preparation (c), synthesised in the
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(Figure 2, B), and we speculate that it may agglomerate to a
poorly absorbable form in the gastrointestinal lumen. However,
overall and consistent with what we have reported previously in
rodent studies,23 we here demonstrate in human subjects that (i) a
ligand-doped Fe(III) oxo-hydroxide nanoparticle [nano Fe(III) (a):
that we now term ‘IHAT’ as it is based upon iron hydroxide adipate
tartrate] can be absorbed ~80% as efficiently as the ‘gold standard’
Fe(II) sulfate and (ii) the nanostructured IHAT is ~3-fold better
absorbed than the simple Fe(III) chloride salt even when
augmented with the same ligands as IHAT (Figure 2, A).
Furthermore, our data suggest that nanosizing and/or destabilising
of the oxo-hydroxide structure is necessary for efficient bioavail-
ability (Figure 1) and that the determinant for bioavailability is
epithelial cellular adhesion/uptake of the intact nanoparticle rather
than gastric acid solubility (Figure 2,B). This is consistent with our
cellular andmurine data but differs from reports where in vitro acid
solubility (pH 1.0) predicts in vivo bioavailability of nanostruc-
tured Fe(III) pyrophosphates and Fe(III) oxides.52 However,
unless molecularly destructured Fe phosphates and Fe oxides are,
likely, too stable for lysosomal dissolution, even when nanosized,
and thus would require gastric conditioning. The finding that a
destructured nanodisperse Fe(III) oxo-hydroxide is utilised in
humans with an efficiency almost equal to pure Fe(II) ions has
important implications for our understanding of dietary iron
digestion and absorption. Based upon murine and cellular models,
we have reported that the uptake of this form of iron is via
endocytosis, without prior requirement formucosal reduction of Fe
(III) to Fe(II).23,25 Following lysosomal dissolution the iron
derived from nano Fe(III) joins the common enterocyte iron pool
and is exported to the systemic circulation via ferroportin
according to body iron needs.24 This mechanism of absorption
resembles that proposed for dietary ferritin and could even
represent a dominant mechanism for absorption of dietary non-
haem iron.27,30,56 Further work should seek to address whether it is
this route or DMT-1 that enables apical uptake ofmost dietary non-
haem iron in humans.
Nonetheless, regardless of its bioavailability and relationship
to the diet, if nanodispersed Fe(III) is to be used for fortificant
and supplemental purposes, its safety must be comparable or
superior to current iron preparations. To this end we considered
here some initial markers of potential toxicity.
One potential concern with current oral iron supplements is
the generation of non-transferrin bound iron (NTBI) in the
systemic circulation following oral Fe(II) sulfate18,57-59 although
the validity and interpretation of these findings remain
controversial.60 Nonetheless, consistent with the idea that the
nano Fe(III) materials have a different mechanism of absorption
to soluble Fe(II) ions the appearance of iron in serum from these
materials was less efficient compared to iron from Fe(II) sulfate,
with lower peak iron and transferrin saturation levels (Figure 3).
Whether this translates to lower NTBI or lower systemic
infection risk needs to be examined, especially when matched
for absolute iron absorption against soluble supplements.
Secondly, in cellular studies with the best-absorbed nano Fe
(III) material [preparation (a): IHAT], we showed that unlike for
Fe(II)maintained soluble with ascorbic acid,40 adverse cellular
effects were detectable only at levels far exceeding luminal ironlevels following supplementation (Figure 4, A). Indeed based
upon a ‘worst case scenario’ of 1 mM luminal Fe concentration
following oral supplementation,40,61,62 IHAT would be at a 7-
fold lower concentration than is required for cellular toxicity to
start. On the other hand soluble ferrous iron is clearly toxic at
this 1 mM concentration.
Thirdly, deposition of ingested nanoparticles in the intestinal
mucosa is a potential concern.63,64 In the rat study presented here,
there were no ultra-structural changes in the small intestine tissue
or abnormal iron deposition in the intestinalmucosa for the nanoFe
(III) material following 14 days of feeding (Figure 4, G). This is
similar to the findings of Hilty et al for other nanostructured iron
materials52 but contrary to what has been observed for some
soluble Fe(III) chelates10,11 which, again, suggests that nano iron
materials may be safer to the gut than soluble iron.
Fourthly, in recent years, undesirable alterations to the intestinal
microbiota have been linked to iron supplementation.7,16,17 The
only human data available suggest that beneficial Bifidobacterium
and Lactobacillus numbers in faeces decrease in favour of
Enterobacter following 6-months of iron supplementation with
electrolytic iron-fortified biscuits.7 In the small in vivo study
presented here, faecal Lactobacillus numbers, far from being
suppressed by the nano iron, appeared to increase, albeit not
significantly with the low study numbers available (Figure 4, D).
Indeed, these observations were from a pilot study in anaemic rats
and, although consistent with the encouraging safety profile of
nano iron in the cellular studies, would benefit from more detailed
follow up. For example, we noted that all iron deficient animals
suffered significant diarrhoea, possibly related to the high
prevalence of colonic Escherichia fergusonii65 that was found in
these severely iron-deplete animals (Figure 3, F), so an ‘otherwise
healthy’ iron deficient phenotypewould be of value in futurework.
It would also be of great interest to test the effect of IHAT/nano Fe(III)
on exacerbation of colon cancer, as this is an especially worrisome
artificial trait of Fe(III) chelates10,11 and, perhaps, is averted for
dietary-like nanoform iron.
In conclusion, fine structures of nano Fe(III) may be directly
absorbed by the human gastrointestinal tract and are efficiently
utilised as a dietary iron source. Initial observations imply superior
safety of this nano Fe versus soluble forms of iron. Further work
should carefully address safety since iron deficiency anaemia is
widely prevalent and there are significant safety concerns with
current forms of soluble supplemental oral iron.Ethical approval statement
The human study was approved by the U.K. National Research
Ethics Service (06/Q0102/47). All participants signed an informed
consent prior to enrolment in the study. The animal study was
approved by the QIMR Berghofer Animal Ethics Committee.Author contributions
DIAP, SFAB,NJRF, GJA,CDV and JJP designed the research;
DIAP, MFA, LKP, MAT and DMF conducted the research;
DIAP andMAT analysed data; NJRF and SFAB provided the iron
1885D.I.A. Pereira et al / Nanomedicine: Nanotechnology, Biology, and Medicine 10 (2014) 1877–1886materials; DIAP and JJP had primary responsibility for
final content. All authors read, provided input to, and approved
the final manuscript.Acknowledgements
This work is a publication of the UK Medical Research
Council. We thank Peter Winship for the stable isotope ICP-MS
analysis and Carol Hutchinson for excellent support with the
human intervention study.Appendix A. Supplementary data
Supplementary data to this article can be found online at
http://dx.doi.org/10.1016/j.nano.2014.06.012.References
1. WHO. The global burden of disease: 2004 update. Geneva: WHO;
2008.
2. De Benoist B, McLean E, Egli I, Cogswell M. Worldwide prevalence of
anaemia 1993-2005. Geneva: WHO; 2008.
3. McLean E, Cogswell M, Egli I, Wojdyla D, de Benoist B. Worldwide
prevalence of anaemia, WHO Vitamin and Mineral Nutrition Information
System, 1993-2005. Public Health Nutr 2008;23:1-11.
4. WHO. The World Health Report. Reducing risks, promoting healthy life;
2002 [Geneva].
5. Ezzati M, Lopez AD, Rodgers A, Vander Hoorn S, Murray CJ. Selected
major risk factors and global and regional burden of disease. Lancet
2002;360(9343):1347-60.
6. Stoltzfus RJ. Iron deficiency: global prevalence and consequences. Food
Nutr Bull 2003;24(4 Suppl):S99-S103.
7. Zimmermann MB, Chassard C, Rohner F, N'Goran EK, Nindjin C,
Dostal A, et al. The effects of iron fortification on the gut microbiota in
African children: a randomized controlled trial in Cote d'Ivoire. Am J
Clin Nutr 2010;92(6):1406-15.
8. Sazawal S, Black RE, Ramsan M, Chwaya HM, Stoltzfus RJ, Dutta A, et
al. Effects of routine prophylactic supplementation with iron and folic
acid on admission to hospital and mortality in preschool children in a
high malaria transmission setting: community-based, randomised,
placebo-controlled trial. Lancet 2006;367(9505):133-43.
9. McDermid JM, Jaye A, Schim van der Loeff MF, Todd J, Bates C,
Austin S, et al. Elevated iron status strongly predicts mortality in West
African adults with HIV infection. J Acquir Immune Defic Syndr
2007;46(4):498-507.
10. Seril DN, Liao J, Ho KL, Warsi A, Yang CS, Yang GY. Dietary iron
supplementation enhances DSS-induced colitis and associated colorectal
carcinoma development in mice. Dig Dis Sci 2002;47(6):1266-78.
11. Radulescu S, Brookes MJ, Salgueiro P, Ridgway RA, McGhee E,
Anderson K, et al. Luminal iron levels govern intestinal tumorigenesis
after apc loss in vivo. Cell Rep 2012;2(2):270-82.
12. Carrier J, Aghdassi E, Cullen J, Allard JP. Iron supplementation
increases disease activity and vitamin E ameliorates the effect in rats with
dextran sulfate sodium-induced colitis. J Nutr 2002;132(10):3146-50.
13. Erichsen K, Ulvik RJ, Grimstad T, Berstad A, Berge RK, Hausken T.
Effects of ferrous sulphate and non-ionic iron–polymaltose complex on
markers of oxidative tissue damage in patients with inflammatory bowel
disease. Aliment Pharmacol Ther 2005;22(9):831-8.
14. Lund EK, Wharf SG, Fairweather-Tait SJ, Johnson IT. Oral ferrous
sulfate supplements increase the free radical-generating capacity of feces
from healthy volunteers. Am J Clin Nutr 1999;69(2):250-5.15. Orozco MN, Solomons NW, Schumann K, Friel JK, de Montenegro AL.
Antioxidant-rich oral supplements attenuate the effects of oral iron on in
situ oxidation susceptibility of human feces. J Nutr 2010;140
(6):1105-10.
16. Werner T, Wagner SJ, Martinez I, Walter J, Chang JS, Clavel T, et al.
Depletion of luminal iron alters the gut microbiota and prevents Crohn's
disease-like ileitis. Gut 2011;60(3):325-33.
17. Dostal A, Chassard C, Hilty FM, ZimmermannMB, Jaeggi T, Rossi S, et
al. Iron depletion and repletion with ferrous sulfate or electrolytic iron
modifies the composition and metabolic activity of the gut microbiota in
rats. J Nutr 2012;142(2):271-7.
18. Hutchinson C, Al-Ashgar W, Liu DY, Hider RC, Powell JJ, Geissler CA.
Oral ferrous sulphate leads to a marked increase in pro-oxidant
nontransferrin-bound iron. Eur J Clin Invest 2004;34(11):782-4.
19. Barton Pai A, Pai MP, Depczynski J, McQuade CR, Mercier RC. Non-
transferrin-bound iron is associated with enhanced Staphylococcus
aureus growth in hemodialysis patients receiving intravenous iron
sucrose. Am J Nephrol 2006;26(3):304-9.
20. van der A DL, Marx JJ, Grobbee DE, Kamphuis MH, Georgiou NA, van
Kats-Renaud JH, et al. Non-transferrin-bound iron and risk of coronary heart
disease in postmenopausal women. Circulation 2006;113(16):1942-9.
21. van Tits LJ, Jacobs EM, Swinkels DW, Lemmers HL, van der Vleuten GM,
de Graaf J, et al. Non-transferrin-bound iron is associated with plasma level
of soluble intercellular adhesion molecule-1 but not with in vivo low-density
lipoprotein oxidation. Atherosclerosis 2007;194(1):272-8.
22. Tripathi AK, Sullivan DJ, Stins MF. Plasmodium falciparum-
infected erythrocytes increase intercellular adhesion molecule 1 expression
on brain endothelium through NF-kappaB. Infect Immun 2006;74(6):3262-70.
23. Powell JJ, Bruggraber SF, Faria N, Poots LK, Hondow N, Pennycook
TJ, et al. A nano-disperse ferritin-core mimetic that efficiently corrects
anaemia without luminal iron redox activity. Nanomedicine 2014, http://
dx.doi.org/10.1016/j.nano.2013.12.011.
24. Aslam MF, Frazer DM, Faria N, Bruggraber SF, Wilkins SJ, Mirciov C,
et al. Ferroportin mediates the intestinal absorption of iron from a
nanoparticulate ferritin core mimetic in mice. FASEB J 2014 [Epub
ahead of print].
25. PereiraDI,Mergler BI, FariaN, Bruggraber SF,AslamMF, Poots LK, et al.
Caco-2 cell acquisition of dietary iron(III) invokes a nanoparticulate
endocytic pathway. PLoS ONE 2013;8(11):e81250, http://dx.doi.org/
10.1371/journal.pone.0081250.
26. Bejjani S, Pullakhandam R, Punjal R, Nair KM. Gastric digestion of pea
ferritin and modulation of its iron bioavailability by ascorbic and phytic
acids in caco-2 cells. World J Gastroenterol 2007;13(14):2083-8.
27. San Martin CD, Garri C, Pizarro F, Walter T, Theil EC, Nunez MT.
Caco-2 intestinal epithelial cells absorb soybean ferritin by mu2 (AP2)-
dependent endocytosis. J Nutr 2008;138(4):659-66.
28. Davila-Hicks P, Theil EC, Lonnerdal B. Iron in ferritin or in salts
(ferrous sulfate) is equally bioavailable in nonanemic women. Am J Clin
Nutr 2004;80(4):936-40.
29. Hoppler M, Schonbachler A,Meile L, Hurrell RF,Walczyk T. Ferritin–iron
is released during boiling and in vitro gastric digestion. J Nutr 2008;138
(5):878-84.
30. Theil EC, Chen H, Miranda C, Janser H, Elsenhans B, Nunez MT, et al.
Absorption of iron from ferritin is independent of heme iron and ferrous
salts in women and rat intestinal segments. J Nutr 2012;142(3):478-83.
31. Pan YH, Sader K, Powell JJ, Bleloch A, Gass M, Trinick J, et al. 3D
morphology of the human hepatic ferritin mineral core: new evidence for a
subunit structure revealed by single particle analysis of HAADF-STEM
images. J Struct Biol 2009;166(1):22-31.
32. Simonian HP, Vo L, Doma S, Fisher RS, Parkman HP. Regional
postprandial differences in pH within the stomach and gastroesophageal
junction. Dig Dis Sci 2005;50(12):2276-85.
33. Beiseigel JM, Hunt JR, Glahn RP, Welch RM, Menkir A, Maziya-Dixon
BB. Iron bioavailability from maize and beans: a comparison of human
measurements with Caco-2 cell and algorithm predictions. Am J Clin
Nutr 2007;86(2):388-96.
1886 D.I.A. Pereira et al / Nanomedicine: Nanotechnology, Biology, and Medicine 10 (2014) 1877–188634. BengtssonA, Scheers N, Andlid T, AlmingerML, Sandberg AS, Svanberg
U. Impaired uptake of beta-carotene by Caco-2 human intestinal cells in the
presence of iron. Int J Food Sci Nutr 2009;60(Suppl 5):125-35.
35. Valberg LS, Taylor KB, Witts LJ, Richards WC. The effect of iron
deficiency on the stomach of the rat. Br J Nutr 1961;15:473-80.
36. FariaN,Winship PD,WeissDJ, ColesBJ, SchoenbergR,HutchisonC, et al.
Development of DRC-ICP-MS methodology for the rapid determination of
Fe-58 erythrocyte incorporation in human iron absorption studies. J Anal At
Spectrom 2011;26(8):1648-52.
37. Ruiz-Arguelles GJ, Diaz-Hernandez A, Manzano C, Ruiz-Delgado GJ.
Ineffectiveness of oral iron hydroxide polymaltose in iron-deficiency
anemia. Hematology 2007;12(3):255-6.
38. Derman DP, Bothwell TH, Torrance JD, Macphail AP, Bezwoda WR,
Charlton RW, et al. Iron absorption from ferritin and ferric hydroxide.
Scand J Haematol 1982;29(1):18-24.
39. Conway RE, Geissler CA, Hider RC, Thompson RP, Powell JJ.
Serum iron curves can be used to estimate dietary iron bioavailability in
humans. J Nutr 2006;136(7):1910-4.
40. Mergler BI, Roth E, Bruggraber SFA, Powell JJ, Pereira DIA.
Development of the Caco-2 model for assessment of iron absorption
and utilisation at supplemental levels. J Pharm Nutr Sci 2012;2
(1):27-34.
41. Rudzki Z, Baker RJ, Deller DJ. The iron-binding glycoprotein of human
gastric juice. II. Nature of the interaction of the glycoprotein with iron.
Digestion 1973;8(1):53-67.
42. WangZ, Li C, EllenburgM, Soistman E, Ruble J,Wright B, et al. Structure
of human ferritin L chain. Acta Crystallogr 2006;62(Pt 7):800-6.
43. Masuda H, Ishimaru Y, Aung MS, Kobayashi T, Kakei Y, Takahashi M,
et al. Iron biofortification in rice by the introduction of multiple genes
involved in iron nutrition. Sci Rep 2012;2:543, http://dx.doi.org/
10.1038/srep00543.
44. Murgia I, Arosio P, Tarantino D, Soave C. Biofortification for combating
‘hidden hunger’ for iron. Trends Plant Sci 2012;17(1):47-55.
45. Sperotto RA, Ricachenevsky FK, Waldow Vde A, Fett JP.
Iron biofortification in rice: it's a long way to the top. Plant Sci
2012;190:24-39.
46. Stein AJ, Meenakshi JV, Qaim M, Nestel P, Sachdev HP, Bhutta ZA.
Potential impacts of iron biofortification in India. Soc Sci Med 2008;66
(8):1797-808.
47. Lopez-Castro JD, Delgado JJ, Perez-Omil JA, Galvez N, Cuesta R, Watt
RK, et al. A new approach to the ferritin iron core growth: influence of
the H/L ratio on the core shape. Dalton Trans 2012;41(4):1320-4.
48. Swain JH, Newman SM, Hunt JR. Bioavailability of elemental iron
powders to rats is less than bakery-grade ferrous sulfate and predicted by
iron solubility and particle surface area. J Nutr 2003;133(11):3546-52.
49. Forbes AL, Arnaud MJ, Chichester CO, Cook JD, Harrison BN, Hurrell
RF, et al. Comparison of in vitro, animal, and clinical determinations of
iron bioavailability: International Nutritional Anemia Consultative
Group Task Force report on iron bioavailability. Am J Clin Nutr
1989;49(2):225-38.
50. Hilty FM, Teleki A, Krumeich F, Buchel R, Hurrell RF, Pratsinis SE, et al.
Development and optimization of iron- and zinc-containing nanostructuredpowders for nutritional applications. Nanotechnology 2009;20
(47):475101.
51. Kapsokefalou M, Alexandropoulou I, Komaitis M, Politis I. In vitro
evaluation of iron solubility and dialyzability of various iron fortificants
and of iron-fortified milk products targeted for infants and toddlers. Int J
Food Sci Nutr 2005;56(4):293-302.
52. Hilty FM, Arnold M, Hilbe M, Teleki A, Knijnenburg JT,
Ehrensperger F, et al. Iron from nanocompounds containing iron
and zinc is highly bioavailable in rats without tissue accumulation. Nat
Nanotechnol 2010;5(5):374-80.
53. Glahn RP, Rassier M, Goldman MI, Lee OA, Cha J. A comparison of
iron availability from commercial iron preparations using an in vitro
digestion/Caco-2 cell culture model. J Nutr Biochem 2000;11(2):62-8.
54. Glahn RP, Wortley GM, South PK, Miller DD. Inhibition of iron uptake
by phytic acid, tannic acid, and ZnCl2: studies using an in vitro
digestion/Caco-2 cell model. J Agric Food Chem 2002;50(2):390-5.
55. Glahn RP, Lee OA, Yeung A, Goldman MI, Miller DD. Caco-2 cell
ferritin formation predicts nonradiolabeled food iron availability in an in
vitro digestion/Caco-2 cell culture model. J Nutr 1998;128(9):1555-61.
56. Kalgaonkar S, Lonnerdal B. Receptor-mediated uptake of ferritin-bound
iron by human intestinal Caco-2 cells. J Nutr Biochem 2009;20
(4):304-11.
57. Schumann K, Solomons NW, Romero-Abal ME, Orozco M, Weiss G,
Marx J. Oral administration of ferrous sulfate, but not of iron
polymaltose or sodium iron ethylenediaminetetraacetic acid
(NaFeEDTA), results in a substantial increase of non-transferrin-bound
iron in healthy iron-adequate men. Food Nutr Bull 2012;33(2):128-36.
58. Dresow B, Petersen D, Fischer R, Nielsen P. Non-transferrin-bound
iron in plasma following administration of oral iron drugs. Biometals
2008;21(3):273-6.
59. Hurrell RF. Safety and efficacy of iron supplements in malaria-endemic
areas. Ann Nutr Metab 2011;59(1):64-6.
60. Lomer MC, Cook WB, Jan-Mohamed HJ, Hutchinson C, Liu DY, Hider
RC, et al. Iron requirements based upon iron absorption tests are poorly
predicted by haematological indices in patients with inactive inflammatory
bowel disease. Br J Nutr 2012;107(12):1806-11.
61. Glover J, Jacobs A. Observations on iron in the jejunal lumen after a
standard meal. Gut 1971;12(5):369-71.
62. SimpsonRJ, Peters TJ. Forms of soluble iron inmouse stomach and duodenal
lumen: significance for mucosal uptake. Br J Nutr 1990;63(1):79-89.
63. Powell JJ, Faria N, Thomas-McKay E, Pele LC. Origin and fate of
dietary nanoparticles and microparticles in the gastrointestinal tract.
J Autoimmun 2010;34(3):J226-33.
64. Powell JJ, Ainley CC, Harvey RS, Mason IM, Kendall MD, Sankey EA,
et al. Characterisation of inorganic microparticles in pigment cells of
human gut associated lymphoid tissue. Gut 1996;38(3):390-5.
65. Chaudhury A, Nath G, Tikoo A, Sanyal SC. Enteropathogenicity and
antimicrobial susceptibility of new Escherichia spp. J Diarrhoeal Dis
Res 1999;17(2):85-7.
66. Hoppe M, Hulthen L, Hallberg L. The validation of using serum iron
increase to measure iron absorption in human subjects. Br J Nutr
2004;92(3):485-8.
